Cencora and DaVita lift guidance

Healthcare guidance is doing something interesting right now. The quarter-to-quarter numbers looked mixed, but the full-year message from Cencora and DaVita was steadier than the headlines suggested. That matters because these are not hype-driven businesses. They sit in the plumbing of care — drug distribution on one side, kidney dialysis on the other — so when both sound confident, investors hear something about demand that goes beyond one quarter. (investor.cencora.com) ### What did Cencora actually say? Cencora reported fiscal second-quarter 2025 results for the period ended March 31, with revenue up 10.3% to $75.5 billion and adjusted diluted EPS up 16.3% to $4.42. The bigger news was the outlook. Management raised full-year adjusted EPS guidance to $1(investor.cencora.com)djusted EPS came in below Wall Street expectations. (investor.cencora.com) ### Why could guidance go up after a miss? Because the miss was not a simple demand-collapse story. Cencora’s U.S. healthcare solutions segment still got help from specialty medicines and GLP-1 drugs, but growth was offset by branded-drug price cuts, lower sales to a large mail-order clie(investor.cencora.com)ed strong. That is why a company can miss the quarter and still sound more confident about the year. (finance.yahoo.com) ### What is “specialty drug” demand doing here? It is the margin engine. Specialty drugs — cancer therapies, autoimmune medicines, complex injectables — are expensive, operationally harder to handle, and more valuable for distributors than plain-vanilla generic pills. Cencora has been leaning harder (finance.yahoo.com)r $1.1 billion and, separately, exited its animal health unit. That tells you management wants more exposure to the higher-value parts of healthcare distribution. (finance.yahoo.com) ### What about DaVita? DaVita’s first-quarter 2025 numbers were cleaner. Revenue came in at $3.224 billion and diluted EPS was $2.00. U.S. dialysis treatments totaled just over 7.04 million in the quarter, or about 91,793 per day. Treatment volume was basically flat sequentially, and normalized non-a(finance.yahoo.com)ization, pricing per treatment, and operating discipline. (investors.davita.com) ### Did DaVita raise guidance too? Not in the company’s May 12, 2025 release. DaVita said it was maintaining its 2025 guidance range for adjusted operating income and adjusted earnings per share. That is still a meaningful signal. The company had dealt with a cyber incident and weaker treatment volume than hoped, but first-qua(investors.davita.com)sage was resilience, not acceleration. (investors.davita.com) ### Why do investors care about these two together? Because they show two different kinds of healthcare demand holding up. Cencora depends on the flow and mix of pharmaceuticals through the system, especially specialty drugs. DaVita depends on recurring dialysis treatments for patients who need care multiple times a week. One (investors.davita.com)Both are defensive in different ways. (investor.cencora.com) ### What is the real read-through? The real read-through is not that healthcare is suddenly booming. It is that core demand in these categories remains stubbornly durable, even when customer churn, reimbursement pressure, cyber disruptions, and pricing changes muddy the quarter. That is w(investor.cencora.com 1)(investor.cencora.com 2) ### Bottom line Cencora and DaVita did not tell the same story. But they pointed to the same underlying fact — healthcare demand in essential categories is still strong enough to support full-year confidence. (investor.cencora.com)